EUCTR2014-000838-39-ES进行中（未招募）1 期
Clinical Trial Phase IIB randomized, multicenter, of continuation or non-continuation with 6 cycles of temozolomide after the first 6 cycles of standard first-line treatment in patients with glioblastoma.
GEINO0 个研究点目标入组 160 人开始时间: 2014年5月8日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Ability to understand and sign the informed consent document .
- •2 . Age greater than or equal 18.
- •3 . Patients with glioblastoma according to WHO classification (glioblastoma ) who received chemo- radiotherapy and temozolomide -based chemotherapy ( Stupp scheme ) and have completed 6 cycles of adjuvant temozolomide (with or without bevacizumab) in the context of standard treatment without presenting progression of disease.
- •4. Availability of tumor tissue from the first surgery for centralized histological review , for determining the MGMT study if you have not done in the center of origin. (If they were made ??in the center of origin the result of the center will be accepted ) .
- •5 . Stable dose of dexamethasone in the inclusion never above corticides dose received in cycle 6 of the adjuvant .
- •6. Index greater than or equal 60 % Karnofsky
- •7. All patients must show no progression of disease in a brain MRI as defined in RANO established criteria before randomization .
- •8. Basal NMR study on a maximum of 6 weeks prior to inclusion, in which no progress is observed and is permitted to manage the care 6th cycle. ( MRI performed after the 6th cycle of adjuvant is also acceptable as long as no progression was observed)
- •9. Adequate bone marrow reserve : hematocrit ? 29% , WBC> 3,000 / mcL , RAN ? 1,500 cells / ul , platelets ? 100,000 cells / ul.
- •10. Creatinine <1.5 times the upper limit of normal of the laboratory performing the analysis.
- •11. Serum bilirubin <1.5 / ULN SGOT , SGPT < 2.5 times the upper limit of normal of the laboratory performing the analysis. Serum < 3/ULN alkaline phosphatases .
- •12. Effective contraceptive method in patients and their partners.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 160
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 160
排除标准
- •1. Less than 5 years of any previous invasive neoplasia. In situ cervical carcinoma or basal cell skin carcinoma accepted.
- •2. Concomitant treatment with other investigational agents (other concomitant bevacizumab) .
- •3. Presence of any clinically significant gastrointestinal abnormalities that may affect the decision , transit or absorption of study drug , such as the inability to take medication in tablets by mouth.
- •4. Presence of any psychiatric or cognitive disorder that limits understanding or written informed consent and / or impair compliance with the requirements of this protocol.
- •5. Concurrent disease that prevents the continuation of treatment temozolomia .
- •6. Any treatment or surgery after initial diagnosis irradiation since starting treatment with radiotherapy and adjuvant temozolomide and ..
- •7. Intratumoral BCNU therapy in surgery for tumor recurrence ( second surgery ) . NOTE : Patients treated with intratumoral BCNU (or what is the same carmustine intratumoral or Gliadel ® ) in the first intervention can participate in the study.
- •8. Presence of leptomeningeal dissemination.
- •9. Pregnant or breastfeeding.
- •10. Positive patients receiving combination antiretroviral therapy in HIV
研究者
相似试验
进行中（未招募）
不适用
Multicenter clinical trial, randomized phase II window of opportunity which aims to test the biological activity of abiraterone acetate administered as neoadjuvant therapy in patients with prostate cancer at high risk. (multicenter study).PROSTATE CANCER PATIENTS WITH HIGH RISKEUCTR2013-000674-30-ITAOU SAN LUIGI GONZAGA - SCDU ONCOLOGIA MEDICA
进行中（未招募）
不适用
ot applicableCoronary Artery DiseaseEUCTR2010-023801-36-NLResverlogix Corp.310
进行中（未招募）
1 期
ot applicableMedDRA version: 14.0Level: PTClassification code 10011078Term: Coronary artery diseaseSystem Organ Class: 10007541 - Cardiac disordersCoronary Artery DiseaseEUCTR2010-023801-36-ESResverlogix Corp.
已完成
2 期
Phase IIb multi-center, double-blind, randomized, parallel group, placebo-controlled clinical trial for the assessment of coronary plaque changes with RVX000222, as determined by intravascular ultrasoundCoronary artery diseasenarrowing coronary10011082NL-OMON35848Resverlogix Corp.40
进行中（未招募）
1 期
ot applicableMedDRA version: 15.0Level: PTClassification code 10011078Term: Coronary artery diseaseSystem Organ Class: 10007541 - Cardiac disordersCoronary Artery DiseaseEUCTR2010-023801-36-BEResverlogix Corp.310